

Special Issue

The Medical Applications of Novel PET Radiopharmaceuticals

Message from the Guest Editors

This medical field is constantly seeking innovative solutions to improve diagnostic and treatment using tailored approaches. One such advancement lies in the utilization of novel positron emission tomography (PET) radiotracers. These cutting-edge radiotracers have shown immense potential in revolutionizing medical applications. With the rapid development of medical imaging technologies, PET has emerged as a powerful tool for visualizing and quantifying physiological processes within the human body. Traditional PET radiotracers have been widely used to diagnose and monitor various conditions. These innovative radiotracers are designed to target specific molecular and cellular processes, allowing for more accurate and precise imaging. This Special Issue aims to explore the significance and impact of novel PET radiotracers toward various medical applications. It is open to original research and review articles. We look forward to receiving your contributions.

Guest Editors

Dr. Jonathan Vigne

1. Department of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000 Caen, France
2. PHIND, Centre Cyeron, Institut Blood and Brain @ Caen-Normandie, INSERM U1237, 14000 Caen, France

Dr. Florent L. Besson

School of Medicine, Université Paris-Saclay, 94270 Le Kremlin-Bicêtre, France

Deadline for manuscript submissions

closed (20 June 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/179676

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)